Targeted adalimumab treatment can optimize long-term outcomes for patients with early RA
Wednesday, May 25, 2011 - 09:30
in Health & Medicine
Data presented today at the EULAR 2011 Annual Congress demonstrated that initial treatment with adalimumab (Humira, ADA) plus methotrexate in early RA patients can provide high levels of disease control in many patients, and may also offer the opportunity to change future treatment options for some.